XV Konferencja Naukowa Polskiego Towarzystwa Hepatologicznego
News
Current issue
Archival Issues
Search
Newsletter
Manuscript Submission
 » 
Journal Abstract
 
Tenofovir in the treatment of chronic hepatitis B
Anna Parfieniuk-Kowerda, Robert Flisiak
Medical Science Review - Hepatologia 2011; 11 41-43
aaICID: 970916
Article type: Review article
IC™ Value: 3.40
Abstract provided by Publisher
 
Tenofovir disoproxil fumarate (TDF) is an acyclic nucleotide analog closely related
to adefovir that has been approved for the treatment of HBV and HIV infection. Clinical studies
confirmed the high efficacy of TDF in suppressing HBV replication in both HBeAg positive and
HBeAg negative patients. Tenofovir was also efficient in the treatment of patients with high
viral load. Hepatitis B virus mutants resistant to other nucleotides/nucleosides analogues were
susceptible to TDF. Tenofovir has high genetic barrier. So far, no HBV variants resistant to TDF
have been selected. This compound is characterized by good safety profile. The risk for emergence
of serious adverse events or renal impairment on treatment with TDF is less than 1%.

ICID 970916

DOI 10.5604/17305039.970916
 
FULL TEXT 102 KB


Related articles
  • in IndexCopernicus™
         tenofowir [0 related records]
         TDF [0 related records]
         HBV [45 related records]
         przewlekłe wirusowe zapalenie wątroby typu B [1 related records]
         Tenofovir [0 related records]
         chronic hepatitis B [24 related records]


  •  

    Copyright © Medical Science Review - Hepatologia  2017
    Page created by Index Copernicus Ltd. All Rights reserved.